Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Completed 4

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 4

Conditions

Melanoma 18Uveal Melanoma 4Prostatic Neoplasms 3Lymphoma, Non-Hodgkin 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Lymphocytic, Chronic, B-Cell 3Burkitt Lymphoma 3Waldenstrom Macroglobulinemia 2Sarcoma 2Salivary Gland Neoplasms 2Recurrent Squamous Cell Lung Carcinoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myeloid, Acute 2Leukemia, Hairy Cell 2Leukemia, Biphenotypic, Acute 2Intraocular Lymphoma 2Hodgkin Disease 2Brain Neoplasms 2Anus Neoplasms 2Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1

Interventions

Ipilimumab 6pembrolizumab 5Nivolumab 5Dacarbazine 5CTLA-4 Antigen 4Carboplatin 3Bevacizumab 3relatlimab 2aflibercept 2Temozolomide 2Ranibizumab 2Radiosurgery 2Paclitaxel 2Lenalidomide 2Immunoglobulin G 2Embolization, Therapeutic 2Disulfides 2Cyclophosphamide 2Colony-Stimulating Factors 2Albumin-Bound Paclitaxel 2AZD 6244 2130-nm albumin-bound paclitaxel 2utomilumab 1ulixertinib 1trametinib 1tebentafusp 1sotrastaurin 1sargramostim 1poly ICLC 1pasireotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has results × Uveal Melanoma × CTLA-4 Antigen × Clear all
NCT03472586 2025-04-24

Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver

Thomas Jefferson University

Phase 2 Completed
14 enrolled 8 charts
Dermatologic

Uveal Melanoma

NCT01585194 2024-07-09

Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

M.D. Anderson Cancer Center

Phase 2 Completed
67 enrolled 12 charts
Dermatologic

Uveal Melanoma

NCT02519322 2024-04-05

Neoadjuvant and Adjuvant Checkpoint Blockade

M.D. Anderson Cancer Center

Phase 2 Completed
53 enrolled 10 charts
Dermatologic

Uveal Melanoma, Melanoma

NCT02158520 2020-01-21

Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery

Academic and Community Cancer Research United

Phase 2 Completed
24 enrolled 10 charts
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡